ANAB:NSD-AnaptysBio Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 23.87

Change

+0.72 (+3.11)%

Market Cap

USD 0.67B

Volume

0.25M

Avg Analyst Target

USD 34.00 (+42.44%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ANAB Stock Forecast & Price:
Based on the AnaptysBio Inc stock forecasts from 4 analysts, the average analyst target price for AnaptysBio Inc is USD 34.00 over the next 12 months. AnaptysBio Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of AnaptysBio Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, AnaptysBio Inc’s stock price was USD 23.87. AnaptysBio Inc’s stock price has changed by +13.61% over the past week, +17.47% over the past month and +2.67% over the last year.

About AnaptysBio Inc (ANAB:NSD)

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of v ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-3.06 (-1.02%)

USD75.25B 29.60 15.72
MRNA Moderna Inc

+3.13 (+1.83%)

USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

+19.34 (+3.11%)

USD67.87B 12.49 9.34
BNTX BioNTech SE

+3.71 (+2.36%)

USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.05 (+0.03%)

USD32.39B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.25 (+0.57%)

USD29.52B 42.40 20.35
ALNY Alnylam Pharmaceuticals Inc

+8.63 (+3.86%)

USD27.16B N/A -34.32
GMAB Genmab AS

+0.56 (+1.59%)

USD22.96B 73.23 6.37
ARGX argenx NV ADR

+0.21 (+0.06%)

USD20.61B N/A -20.22

ETFs Containing ANAB

Symbol Name Weight Mer Price(Change) Market Cap
UNIC:LSE Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

+0.34 (+2.83%)

N/A
DRUP:XETRA Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

+0.20 (+1.69%)

USD0.18B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.31% 55% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.31% 55% F 35% F
Trailing 12 Months  
Capital Gain 3.24% 85% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.24% 85% B 83% B
Trailing 5 Years  
Capital Gain 8.55% 69% D+ 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.55% 68% D+ 43% F
Average Annual (5 Year Horizon)  
Capital Gain -0.73% 51% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.73% 50% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 69.08% 37% F 19% F
Risk Adjusted Return -1.06% 50% F 41% F
Market Capitalization 0.67B 75% C 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 95.42 9% F 11% F
Price/Book Ratio 1.79 56% F 48% F
Price / Cash Flow Ratio -14.65 85% B 80% B-
EV/EBITDA -1.60 59% F 68% D+
Management Effectiveness  
Return on Equity -31.31% 77% C+ 31% F
Return on Invested Capital -15.09% 85% B 34% F
Return on Assets -11.82% 86% B 29% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 15.39 4% F 3% F
Short Percent 20.38% 5% F 8% F
Beta 0.15 92% A- 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector